Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    +1.76 (+2.16%)
     
  • Gold

    2,254.80
    +42.10 (+1.90%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0793
    -0.0036 (-0.33%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2626
    -0.0012 (-0.10%)
     
  • USD/JPY

    151.3810
    +0.1350 (+0.09%)
     
  • Bitcoin USD

    70,683.62
    +1,617.90 (+2.34%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Read How Analysts Reacted To Salesforce's Q4 Results

  • Analysts adjusted their price targets on Salesforce.com Inc (NYSE: CRM) post Q4 results.

  • Citi analyst Tyler Radke raised the firm's price target on Salesforce to $233 from $220 (11.5% upside) and kept a Neutral.

  • The company "delivered a reassuring" Q4 and outlook, which should help alleviate concerns around the health of the front office and general IT spending.

  • UBS analyst Karl Keirstead raised the firm's price target on Salesforce to $225 from $210 (7.8% upside) and kept a Neutral.

  • The company's Q4 results were "solid," and evidence suggests that its growth profile is proving to be "durable" even with the second anniversary of the pandemic approaching.

  • Piper Sandler analyst Clarke Jeffries maintained Salesforce with an Overweight and lowered the price target from $365 to $330 (58% upside).

  • Price Action: CRM shares traded higher by 3.89% at $217.01 in the premarket on the last check Wednesday.

Latest Ratings for CRM

Mar 2022

Wedbush

Maintains

Outperform

Mar 2022

Canaccord Genuity

Maintains

Buy

Mar 2022

Raymond James

Maintains

Strong Buy

View More Analyst Ratings for CRM

View the Latest Analyst Ratings

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement